InvestorsHub Logo
Followers 5
Posts 554
Boards Moderated 0
Alias Born 04/17/2012

Re: longusa post# 3236

Tuesday, 01/07/2014 2:14:02 PM

Tuesday, January 07, 2014 2:14:02 PM

Post# of 704269
long, I would like to think that is NWBO's gameplan. And that potential to expand the platform rapidly is what attracted me to the company (apart from demonstrated efficacy, with an excellent safety profile), first in 2008. Would love to see what you said play out.

Flipper, I don't think management has bandwidth for DCVax-Prostate right now. Also, any potential partners may want to wait for early DCVax-Direct results to gauge the efficacy of the improved DCVax platform in general. Also, I wonder if there aren't efforts on in the background to try and subsume the DCVax-Prostate technology into a more generic DCVax platform (perhaps with a tweak for prostate cancer i.e. loading prostate specific membrane antigens ?). The following is from Dr. Marnix Bosch's presentation at the Brain Tumor Biotech Summit on 07-Jun-2013. The slide was on the potential indications for which DCVax-Direct can be applicable. Note the mention of prostate cancer...

Potential indications: all non-resectable (inoperable)
solid tumors, such as:
o Liver cancer
o Liver metastases of colon cancer
o Head and neck cancer
o Esophageal cancer
o Prostate cancer
o Other cancers
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News